Fred Aslan
CEO at Artiva Biotherapeutics, Inc. (ARTV); CEO, President at Artiva Biotherapeutics, Inc. (ARTV)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 7SEC | ARTVArtiva Biotherapeutics, Inc. | Sell Plan | 23,4631,519,606 held (−2%) | $7.20 | $169K | -3.6% |
| Oct 6SEC | ARTVArtiva Biotherapeutics, Inc. | Sell | 61,6961,543,069 held (−4%) | $6.84 | $422K | +1.5% |
| Sep 9SEC | ARTVArtiva Biotherapeutics, Inc. | Sell Plan | 23,4291,449,765 held (−2%) | $10.92 | $256K | -36.4% |
| Sep 4SEC | ARTVArtiva Biotherapeutics, Inc. | Sell | 61,8881,473,194 held (−4%) | $11.16 | $691K | -37.8% |
| May 19SEC | ARTVArtiva Biotherapeutics, Inc. | Sell | 27,1161,535,082 held (−2%) | $9.01 | $244K | -23.0% |
| Dec 15SEC | ARTVArtiva Biotherapeutics, Inc. | Sell Plan | 3,1871,209,948 held (−0%) | $6.00 | $19K | +15.7% |
| Nov 17SEC | ARTVArtiva Biotherapeutics, Inc. | Sell Plan | 6,375343,999 held (−2%) | $3.38 | $22K | +105.3% |
| Oct 17SEC | ARTVArtiva Biotherapeutics, Inc. | Sell Plan | 25,500356,721 held (−7%) | $6.00 | $153K | +15.7% |
- Sell
CEO Fred Aslan sold $169K of ARTV at $7.20 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Fred Aslan sold $256K of ARTV at $10.92 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Fred Aslan sold $19K of ARTV at $6.00 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Fred Aslan sold $22K of ARTV at $3.38 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Fred Aslan sold $153K of ARTV at $6.00 — pre-scheduled 10b5-1 plan sale.